As chronic inflammation and the incidence or the recurrence of thyroid cancer are highly related 30 and, moreover, increased NF‐κB activation in thyroid cancer cell lines and tissues has long been documented 8, we hypothesize that Escin would benefit the patients with thyroid cancer. Here, NFKB1 is linked to thyroid gland carcinoma.